Eisai stock
Price history
+12.94% over the period1 year: from ¥4,675.00 (November 17, 2025) to ¥5,280.00 (November 16, 2026), +12.94%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | ¥5,280.00 |
| October 30, 2026 | ¥5,052.00 |
| September 30, 2026 | ¥4,855.00 |
| August 31, 2026 | ¥4,740.00 |
| July 31, 2026 | ¥4,828.00 |
| June 30, 2026 | ¥4,119.00 |
| May 29, 2026 | ¥3,984.00 |
| April 30, 2026 | ¥4,687.00 |
| March 31, 2026 | ¥4,871.00 |
| February 27, 2026 | ¥5,241.00 |
| January 30, 2026 | ¥4,311.00 |
| December 30, 2025 | ¥4,660.00 |
| November 28, 2025 | ¥4,897.00 |
| November 17, 2025 | ¥4,675.00 |
At a glance
The company
Research, develop, manufacture and sell pharmaceuticals including oncology, neurology and other therapeutic treatments
Latest results
Quarter to September 30, 2026 · EPS ¥41.47 (estimate ¥56.31)
Next event
TickerLandia's take on Eisai
- Priced as usual relative to earnings: P/E on the latest fiscal year 39 vs a median of 37 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 33 vs 28 (+17%) in a group of 11.
- Strong point: Dividend (86/100 in its group). Weak point: Profitability (26/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−0.08% from the 52-week high
Analysts · 14 analysts
Average target¥4,625.00−12.41% vs. price
Buy 4 · Hold 9 · Sell 1 · Buy
TickerLandia Fingerprint: Eisai
Compared with similar companies: very high dividend and very high earnings stability.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Priceaverage41
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 33.3 64 Forward P/E 25.6 65 EV/EBITDA 14.5 43 Price/book 1.63 22 Price/sales 1.63 12 Profitabilitylow26
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 76.8% 73 Operating margin 6.7% 12 Net margin 4.9% 17 ROE 5.1% 17 ROA 2.5% 12 Earnings stabilityvery high81
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 0.4% 99 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthaverage55
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +15.10% 66 Revenue growth (year over year) +19.40% 72 Average revenue growth (3 years) +3.50% 25 Financial strengthhigh62
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.28 59 Current ratio 2.33 60 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −1.32 85 Interest coverage 10.4 42 Dividendvery high86
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 3.1% 85 Payout ratiopays out more than its earnings 102.8% 92 Consecutive dividend years 27 years 80 Market momentumstrong75
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +19.55% 86 Relative strength (6 months) +14.38% 73 Distance from 200-day average +11.47% 82 1-year return +15.17% 62 Risklow29
How much the price swings.
Metric Value Position in group Volatility (60 days) 30.8% 35 Maximum drawdown (12 months) 29.0% 39 Beta (1 year) 0.13 13
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Eisai is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2026), Eisai's P/E today is 38.6, in line with the median of its last 10 fiscal years (36.5; between 18.7 and 50.5 from 2017 to 2026). Eisai's P/E (trailing 12 months): 33.3, +17% against the median of a group of 11 similar companies (28.4).
Compared with 11 similar companies
| Metric | Eisai | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 33.3 | Middle | |
| Forward P/E | 25.6 | Middle | |
| Operating margin | 6.7% | Low | |
| ROE | 5.1% | Low | |
| Debt/equity | 0.28 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Eisai. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥235.63B
Latest quarter · Q3 2026
Net income
¥11.69B
Latest quarter · Q3 2026
Quarterly net margin
5.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥1.46T
- P/E
- 33.3
- EPS
- ¥155.59
- Volume
- 1.57M
- Daily trading
- €40.54M
- Dividend yield
- 3.03%
- Last ex-dividend on September 29, 2026
How Eisai is changing
All resultsRevenue grew 5.0% a year on average over the last 5 years
Free cash flow equal to 83% of net income
Returns
Eisai returns with dividends
¥1,000 invested in Eisai 5 years ago, on November 16, 2021, would be worth ¥734 today with dividends reinvested: −26.60% in total, −6.00% per year. On price alone it would be ¥639 (−36.10%).
| Period | Eisai | Nikkei 225 | ¥1,000 becomes |
|---|---|---|---|
| 1 month | +7.32% | −6.39% | ¥1,073 |
| 6 months | +11.79% | −0.42% | ¥1,118 |
| Year to date | +13.30% | +21.48% | ¥1,133 |
| 1 year | +16.70% | +21.52% | ¥1,167 |
| 3 years | −24.91% | +82.95% | ¥751 |
| 5 years | −26.60% | +105.15% | ¥734 |
| 10 years | −2.78% | +242.35% | ¥972 |
Over the last 6 months it has done better than 44% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment
The chart in detail
Eisai: technical analysis
Eisai is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 58.5% below its all-time closing high (¥12,710.00, June 22, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 62
- Between 30 and 70
- vs 200-session average
- +13.39%
Active signals
New 52-week high.
Support and resistance
Price areas where Eisai has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price¥5,280.00
- Support¥5,253.33−0.51%3 touches, last on November 5, 2026
- Support¥5,157.33−2.32%3 touches, last on October 23, 2026
- Support¥5,021.50−4.90%2 touches, last on September 25, 2026
Volatility and risk
Over the last year it has moved little with the Nikkei 225.
- Beta (1 year) vs Nikkei 225
- 0.13
- Volatility (60 sessions, annualised)
- 30.4%
- Largest fall in the last year
- −28.96%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Eisai: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Eisai has been June: +2.71% on average, positive in 20 years out of 37. The weakest has been January: −1.86% on average, positive in 10 years out of 36. November, the current month, has been positive in 20 years out of 36 (+0.05% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −1.86% | −1.40% | 10 of 36 |
| February | +1.18% | −0.52% | 18 of 37 |
| March | −1.12% | −2.17% | 13 of 37 |
| April | +0.53% | 0.00% | 17 of 37 |
| May | +1.01% | +0.73% | 22 of 37 |
| June | +2.71% | +1.18% | 20 of 37 |
| July | +0.02% | −0.24% | 17 of 37 |
| August | +1.56% | +2.78% | 23 of 37 |
| September | +1.62% | +1.12% | 19 of 37 |
| October | +0.46% | −1.47% | 14 of 37 |
| November | +0.05% | +0.92% | 20 of 36 |
| December | +1.01% | +1.45% | 24 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Eisai and its competitors
Eisai is known mainly through Lenvima, LEQEMBI and Dayvigo, the products of a Japanese pharmaceutical company that researches, develops, manufactures and sells drugs in Japan and abroad. Its focus lies in neurology and oncology, and its range includes prescription drugs and over-the-counter medicines. LEQEMBI is a humanized IgG1 monoclonal antibody against amyloid-beta protofibrils, Lenvima is a multi-kinase inhibitor involved in tumor angiogenesis, and Dayvigo is a novel small molecule compound. Sales extend to Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia and the Global South.
- Headquarters
- Tokyo, Japan
- Employees
- 10,543
- Founded
- 1941
- Chief executive
- Haruo Naito
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Eisai4523 | $9.14B | 6.7% | 33.3 | +11.79% |
| Kyowa Kirin4151 | $8.46B | 21.8% | 16.6 | +9.73% |
| CiplaCIPLA | $11.93B | 13.0% | 38.8 | −2.63% |
| Zhejiang NHU002001 | $12.3B | 33.8% | 10.9 | −21.99% |
| Zydus LifesciencesZYDUSLIFE | $12.59B | 17.2% | 28.4 | +17.82% |
| Laurus LabsLAURUSLABS | $13.9B | 24.1% | 97.8 | +67.72% |
Same industry or related industries, similar size. Compare Eisai with its competitors · Full profile
